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Abstract: 3-(β-D-Glucopyranosyl)-5-substituted-1,2,4-triazoles have been revealed as an 
effective scaffold for the development of potent glycogen phosphorylase (GP) inhibitors but 
with the potency very sensitive to the nature of the alkyl/aryl 5-substituent (Kun et al., Eur. J. 
Med. Chem. 2014, 76, 567). For a training set of these ligands, quantum mechanics-polarized 
ligand docking (QM-PLD) demonstrated good potential to identify larger differences in 
potencies (predictive index PI = 0.82) and potent inhibitors with Ki’s < 10 µM (AU-ROC = 
0.86). Accordingly, in silico screening of 2335 new analogues exploiting the ZINC docking 
database was performed and nine predicted candidates selected for synthesis. The compounds 
were prepared in O-perbenzoylated forms by either ring transformation of 5-β-D-
glucopyranosyl tetrazole by N-benzyl-arenecarboximidoyl chlorides, ring closure of C-(β-D-
glucopyranosyl)formamidrazone with aroyl chlorides, or that of N-(β-D-
glucopyranosylcarbonyl)arenethiocarboxamides by hydrazine, followed by deprotections. 
Kinetics experiments against rabbit muscle GPb (rmGPb) and human liver GPa (hlGPa) 
revealed five compounds as potent low µM inhibitors with three of these on the 
submicromolar range for rmGPa. X-ray crystallographic analysis sourced the potency to a 
combination of favorable interactions from the 1,2,4-triazole and suitable aryl substituents in 
the GP catalytic site. The compounds also revealed promising calculated pharmacokinetic 
profiles.  
 
Keywords: 1,2,4-triazole, C-β-D-glucopyranosyl derivatives, glycogen phosphorylase 
inhibitors, QM/MM docking, kinetics, X-ray crystallography 
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1. Introduction 
Type 2 diabetes (T2D) is a heterogeneous disease characterized by hyperglycemia. The 
incidence of diabetes is on the rise globally with approximately 422 million people currently 
affected and with ~90% of these cases T2D [1]. Current approaches to management of T2D 
include modifications to diet, regular exercise and prescribed oral antihyperglyaemic drugs. 
Adequate control of blood glucose levels is crucial to reduce the incidence of the long term 
complications of T2D such as nephropathy, neuropathy and an increased risk of blindness and 
cardiovascular disease [2]. However, current antihyperglycaemic drugs have somewhat 
limited efficacy in this regard. 
 
Glycogen phosphorylase (GP; EC 2.4.1.1) is a validated target for the development of new 
T2D treatments having a direct influence on blood glucose levels through the glycogenolysis 
pathway [3]. Structurally, GP exists as a homodimer consisting of two identical subunits, each 
842 residues long. It is regulated allosterically by phosphorylation, has pyridoxal-5-phosphate 
(PLP) as co-factor, and exists in two interconvertible forms: the phosphorylated 
predominantly active R state (GPa), and the unphosphorylated predominantly inactive T state 
(GPb). Seven different GP binding sites have been identified to date offering multiple 
opportunities for modulation of enzymatic activity [4-6]: the catalytic, allosteric, new 
allosteric, inhibitor, glycogen storage, benzimidazole [7] and quercetin binding site [8]. A 
large number of synthetic and natural product GP inhibitors targeting the different binding 
sites have been identified in recent years and solved structures of inhibitor bound GP 
complexes have facilitated further structure based inhibitor design efforts [4, 5, 9]. GP 
inhibitors have demonstrated considerable potential for T2D treatment in cellular models [10-
12] and in vivo [13-16], as well as promise against other conditions such as myocardial and 
cerebral ischemias, and tumors [17-19]. 
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Of the different GP binding sites, the catalytic site has been explored most in terms of 
inhibitor design efforts. The physiological inhibitor of GP is α-D-glucose (Ki = 1.7 mM) and 
rational design of α and β-substitutions at the anomeric carbon have proved effective towards 
increasing inhibitor potency [4, 5, 9, 20, 21]. β-Substitutions have proved particularly 
effective by exploiting favorable interactions in the so-called β-cavity of the catalytic site, a 
pocket lined by both polar and non-polar residues. Choice of the linker group which connects 
the glucose moiety with different alkyl/aryl substituents is critical to inhibitor potency [4]. 
Among recently reported potent catalytic site inhibitors [22, 23], C-glucopyranosyl-1,2,4-
triazoles have been revealed as a novel scaffold (Table 1) for the design of potent GP 
inhibitors [23, 24] with I and II exhibiting potencies of 0.41 and 0.67 µM, respectively. The 
potencies, however, are very sensitive to the alkyl/aryl ligand substituent occupying the β-
cavity, with 50% of the compounds reported to date (X-XVIII) having Ki’s > 100 µM to no 
inhibition.  
 
With this in mind, we report here the exploitation of the C-glucopyranosyl-1,2,4-triazole 
skeleton (Table 1) for the design of new potent GP inhibitors. Using the previously reported 
compounds with known inhibition constants (Ki’s) as a training set (Table 1) [23, 24], we 
have investigated different docking methods to reproduce the trends in binding affinities for 
this congeneric series of compounds. Quantum mechanics/molecular mechanics (QM/MM) 
docking in the form of quantum mechanics – polarised ligand docking (QM-PLD) with Glide 
and QSite [25] was found to perform best as determined by a rigorous statistical analysis. 
Then, exploiting the ZINC docking database (http://zinc.docking.org/) [26], different –R 
groups (with a basic substructure phenyl) from commercially available acids, acid chlorides 
and aldehydes led to the virtual screening of 2335 new C-glucopyranosyl-1,2,4-triazole 
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analogues. Nine of the screened candidates were selected for synthesis and extensive kinetics 
studies performed. Five of the nine candidates revealed potencies better than the threshold 
employed for ’activity’ (Ki < 10 µM) with three compounds in the upper-nanomolar range for 
rmGPa. These inhibitors are among the most potent catalytic site inhibitors discovered to 
date. Crystallographic studies have been performed and these structural studies have revealed 
the interactions that govern the observed potencies. Favorable pharmacokinetic profiles are 
critical to the effectiveness of these inhibitors at the cellular level and in vivo. In this regard, 
absorption, distribution, metabolism and excretion (ADME) predictions are additionally 
reported and analyzed.  
 
Table 1. Training set of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles with their 
inhibition data towards rmGPb.[23] 
 
O
OH
HO
HO
OH
N
NHN
R
 
 
 R Ki [µM]  R Ki [µM] 
I 
 
0.41 X   -CH2OH 105 
II 
 
NH2
 
0.67 XI 
  
CF3
 
111 
III 
 
CH3
 
1.7 XII -CH3 499 
IV 
OCH3
 
1.9 XIII 
 
OCH3
OCH3
OCH3
 
518* 
V 
OH
 
2.9 XIV 
 
N
 
 
707 
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VI 
 
 
7 XV 
  
C(CH3)3
 
778 
VII 
 
NH2
NH2
 
14 XVI -C(CH3)3 no inh. 
at 625 µM 
VIII 
NO2
 
33.5 XVII 
     
 
COOH
    
 
no inh. 
at 625 µM 
IX 
CH3
CH3
 
39.7 XVIII 
 
NO2
NO2
 
no inh. 
at 625 µM 
*Calculated from the IC50 value by using a web-based tool.[27] 
 
2. Results & Discussion 
2.1 In Silico Selection of Synthetic Candidates 
2.1.1 Training Set Results 
The training set of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles used in this study 
represent a congeneric series of 18 compounds (Table 1) with a good spread of Ki values 
ranging from 0.41 µM to no inhibition [23, 24]. ‘Activity’ was defined in terms of inhibitor 
potency throughout. Performance of different docking methods, Glide-SP (standard-
precision), -XP (extra-precision) and QM-PLD with respect to the prediction of ligand 
activities was analyzed in a statistical manner. The correlation between predicted and 
experimental activities was measured using the Pearson (RP) and Spearman (RS) correlation 
coefficients, which quantify the relative strength (and direction) of a relationship. Rp is 
parametric and takes into account the absolute differences between experimental data (binding 
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free energies) and predictions (docking score); RS describes the non-parametric relationship 
between the activity ranks of the ligands in the two datasets. Rp is a better measure for 
absolute predictions (binding affinities), with RS more appropriate for relative ranking[28, 29] 
and therefore assumes priority over Rp in this work. Additionally, we considered the 
‘predictive index’ (PI) [30]. This metric provides an important additional measure for the 
relative ranking of ligand potencies by using a weight that depends on the difference between 
the experimental activities of ligands. Therefore, the PI reflects that a good model should be 
able to differentiate ligands which have larger differences in potencies, whereas if potencies 
are similar, the weight will be low. PI values range from -1 (predictions always wrong) to +1 
(predictions always right), with 0 corresponding to predictions that are completely random. 
Finally, the area under the ROC (AU-ROC) curve metric was calculated for each docking 
model representing the probability of active compounds being ranked earlier than inactive 
compounds (range 0-1). For AU-ROC, we used a threshold of Ki < 10 µM to define activity, 
leading to n = 6 actives in the set of N = 18 compounds.  While a smaller dataset alters the 
shape of the null distributions (Figure 1), it does not limit its application to studies of this 
type, which has also included the CSAR benchmark exercises [29].  The statistical metrics 
used in our analysis are described in more detail in the Supplementary Information.  
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Figure 1. Comparison of AU-ROC null distributions for a set of n = 6 actives in a set of 18 
ligands (this study) versus a representative set of n = 10 actives in a set of 1000 ligands used 
in larger scale virtual screening. Distributions were created by random selection of ligands 
and calculation of AU-ROC for each of these selections using the program R [31]. With a 
smaller pool of ligands, random selection of the best or worst subset is more likely, hence the 
wider and shorter distribution on the left. Statistically significant models, however, will still 
be indicated by p-values < 0.05. 
The results for statistical analysis of docking performance are shown in Table 2. Improvement 
of results with increasing ‘accuracy’ of the docking algorithms was observed from Glide-SP 
(Rp = 0.59, RS = 0.65, PI = 0.70) to –XP (Rp = 0.73, RS = 0.73, PI = 0.77). A high AU-ROC 
value of 0.89 for Glide-XP was obtained indicating the efficiency of the algorithm to 
recognize inhibitors with Ki’s less than the 10 µM threshold value.  Superior performance of 
QM/MM docking approaches has previously been reported [32-35], including for the GP 
catalytic site [34]. QM-PLD involved reparametrization of the ligand atomic charges in the 
field of the receptor using single point QM/MM calculations, with the ligand representing the 
QM region and described using B3LYP/LACVP* [36-40]. Using these new electrostatic 
potential (ESP) fit ligand charges, ligands were redocked using Glide-XP. For QM-PLD, 
while the Rp (0.71) and AU-ROC (0.86) values were similar to those from Glide-XP, metrics 
reflecting performance with respect to relative ranking of activities were improved for QM-
PLD (RS = 0.77, P.I. = 0.82). A PI value of 0.82 is comparable to a PI value of 0.84 obtained 
for a congeneric series of 16 p38 MAP kinase protein using computationally expensive 
thermodynamic integration (TI) free energy simulations [30]. Overall, while QM-PLD did 
produce reasonable correlation between predicted and experimental values for scores and 
affinity, respectively (Pearson Rp = 0.71), and relative ranking of potencies (Spearman Rs = 
0.77), it demonstrated better potential to identify larger differences in potencies (predictive 
index PI = 0.82) and potent inhibitors with Ki’s < 10 µM (AU-ROC = 0.86).  This suggested 
the potential of QM-PLD to correctly propose potent 3-(β-D-glucopyranosyl)-5-substituted-
1,2,4-triazole analogues at the screening stage. Probabilities (p-values) which reflect the 
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robustness of the predictions were all << 0.05 (Table 2) and validate their statistical 
significance. 
Table 2. For the training set of eighteen 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles (Table 
1), statistical analysis of the agreement between docking and experimental activities as described in 
the text.a 
 Pearson Correlation Spearman Correlation     
Method RP p-value t-value RS p-value t-value PI p-value AU-ROC p-value 
Glide-SP 0.59 0.020 2.64 0.65 0.008 3.11 0.70 0.0029 0.76 0.0352 
Glide-XP 0.73 0.002 3.83 0.73 0.003 3.80 0.77 0.0007 0.89 0.0035 
QM-PLD  0.71 0.003 3.64 0.77 0.001 4.37 0.82 0.0002 0.86 0.0064 
a
 The best values for each metric are highlighted in bold. For the correlation coefficients Rp and Rs, p-values are 
derived from the t-distribution (t-values) for n - 2 degrees of freedom (13). 
 
2.1.2 Screening Set Results 
Based on the training set results, virtual screening of 2335 new 3-(β-D-glucopyranosyl)-5-
substituted-1,2,4-triazoles was performed using QM-PLD. As all training set ligands were 
predicted to preferentially bind in one tautomeric state of the 1,2,4-triazole (tautomer shown 
in Table 1) forming hydrogen bond interactions with His377 O, only this tautomeric state was 
considered in the calculations. This favorable interaction was later confirmed in our 
crystallographic studies (vide infra). Nine candidates (target compounds 10a-f and 10h-j as 
per Scheme 1 and Table 3) were selected for synthesis based on the novelty of their chemical 
structure, docking scores, predicted interactions with GPb, synthetic viability and commercial 
availability of starting materials. 10g was not screened but was of academic interest. 
2.2 Syntheses 
 
The target compounds were prepared by adapting our methods for the synthesis of C-
glucopyranosyl 1,2,4-triazoles (Scheme 1) [23, 24, 41-43]. Synthetic studies were started by 
transformations of tetrazole 1 [44] since this method proved to be the most versatile one in 
previous investigations (Route A) [23]. Thus, N-benzyl arenecarboxamides 5 were treated 
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with SOCl2 to give imidoyl chlorides which, without isolation and purification, were reacted 
with 1 in boiling xylene to result in the corresponding fully protected 1,2,4-triazole 
derivatives 6aa, ba, and c-e. Removal of the benzyl protecting groups by catalytic 
hydrogenation furnished 7a-d which were further deprotected to 10a-d by the Zemplén 
protocol. Protective group cleavage of 6d and 6e was also effected in a reversed order to give 
9d and 9e under Zemplén conditions. Catalytic hydrogenolysis of 9e yielded 10e, however, N-
benzyl cleavage failed from 9d even at higher temperature and pressure in a sealed tube. In 
order to get the sulfamoylated derivatives 10f and g, tosyl amidrazone 2 was acylated [24, 43] 
by 4-sulfamoylbenzoyl chlorides to 7f and g which, on Zemplén transesterification, produced 
10f and g, respectively (Route B). None of these methods proved suitable to prepare triazoles 
7h-j which could, however, be obtained via Route C [42]. Thus, anhydro-aldonic acid 3 was 
converted to the corresponding acid chloride 4 [45] which was reacted with thioamides to 
give the N-(β-D-glucopyranosylcarbonyl)thioamides 8h-j. Ring closure of compounds 8 by 
hydrazine hydrate furnished 1,2,4-triazoles 7h-j which were then O-debenzoylated by the 
Zemplén method to the target compounds 10h-j. 
 
Scheme 1. Synthesis of the target C-glucopyranosyl 1,2,4-triazoles 10. 
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N
Cl
Bn
O
OBz
BzO
BzO
OBz
N
N
NHN
Ar NHBn
O
O
OBz
BzO
BzO
OBz
NHNHTs
NH
O
OBz
BzO
BzO
OBz
N
H
O
Ar
S
H2N Ar
S
3 X = OH
4 X = Cl
ii
Ar
1
5
2
8
O
OBz
BzO
BzO
OBz O
X
O
OBz
BzO
BzO
OBz
N
NN
6
Ar
Bn
O
OBz
BzO
BzO
OBz
N
NHN
7
Ar
O
OH
HO
HO
OH
N
NN
9
Ar
Bn
O
OH
HO
HO
OH
N
NHN
10
Ar
Route A Route B Route C
i
ii
iii
iv
v
vii vii
viii
vi
Reagents and conditions: i) anhydr. m-xylene at boiling temp.; ii) SOCl2 at boiling temp.; iii) 1. 
ArCOCl, anhydr. CHCl3, pyridine 0 °C → rt, 2. Bu4NF, THF at boiling temp.; iv) anhydr. CH3CN, 
pyridine, rt; v) H2 (1 atm), Pd(C), anhydr. EtOAc or THF, both at boiling temp.; vi) NH2NH2·H2O, 
pyridine, rt; vii) cat. NaOMe, anhydr. MeOH, CHCl3, rt; viii) H2 (1 atm), Pd(C), anhydr. MeOH, 
EtOAc at boiling temp. 
 
 
Table 3: Structure of the aromatic moieties (Ar) for the compounds in Scheme 1 and the 
corresponding yields of the reactions. 
Ar 
 
Route 
Isolated yield 
 6 7 8 9 10 
 
aa A 63 - - - - 
 
a A - 62 - - 76 
 
ba A 64 - - - - 
 
b A - 77 - - 77 
 
c A 37 86 - - 52 
 
d A 64 60 - 97 94 (from 7) 
 
e A 46 - - 81 81 
 
f B - 47 - - 75 
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g B - 42 - - 56 
 
h C - 70 71 - 90 
 
i C - 65 58 - 70 
 
j C - 74 81 - 90 
 
2.3 Enzyme Kinetics 
The inhibition constant value (Ki) of the synthesized compounds for human liver glycogen 
phosphorylase a (hlGPa) together with the values for rmGPa (to compare the effect of the 
compounds in the liver and muscle) and rmGPb (to validate structural data) are summarized 
in Table 4. As the data shows for rmGPb, inhibitors 10a-d are almost equipotent (Ki’s 1.19 – 
5.05 µM) while 10h is somewhat less potent (Ki = 11.50 µM) and close to our threshold value 
for ‘activity’ (Ki < 10 µM). Compounds 10e, 10f and 10i are moderate inhibitors (Ki’s 20 – 
98.2 µM) while 10j and 10g do not show any significant inhibition. However, there were 
some solubility issues for 10j, while 10g was not one of our predicted compound. From the Ki 
values it seems that completely non-polar substituents like fluorene (10c) or biphenyl (10d) 
increase the potency more than more polar ones like carboxy-biphenyl (10a) and carboxy-
naphthyl (10b), or at least the effect of the polar carboxylate groups on potency is neutral. Of 
significant interest is the fact that the change of the position of the second phenyl ring at the 
biphenyl substituent from the meta position (10e) to the para (10d) leads to an approximately 
28-fold increase in potency. Compounds 10a (Ki = 0.98 µM), 10b (Ki = 0.78 µM) and 10c (Ki 
= 0.84 µM) show a preference for rmGPa with sub-micromolar activity observed, while 10d 
displays similar potency for all three enzymes.  
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Table 4. Inhibition of glycogen phosphorylases by the synthesized compounds and crystallographic numbering. 
Code Compounds Ki (µM) 
rmGPb rmGPa hlGPa 
10a 
 
4.42 ± 0.17 0.98 ± 0.04 2.67 ± 0.12 
10b 
 
5.05 ± 0.40 0.78 ± 0.05 3.88 ± 0.13 
10c 
 
1.19 ± 0.13 0.84 ± 0.07 2.02 ± 0.33 
10d 
 
2.38 ± 0.19 2.09 ± 0.18 2.23 ± 0.08 
10e 
 
68.2a N. m.b N. m.b 
10f 
 
98.2a N. m.b N. m.b 
10g 
 
no inh. at 625 µM N. m.b N. m.b 
10h 
 
11.50 ± 0.23 3.38 ± 0.28 8.91 ± 0.44 
10i 
 
20 ± 0.95 N. m.b N. m.b 
10j 
 
>1.5 mM N. m.b N. m.b 
a
 Calculated from the IC50 value by using a web-based tool [27]. 
b Not measured. 
 
2.4 X-ray Crystallography 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
The rmGPb-ligand complexes of the most potent inhibitors from the kinetics studies (10a-d, 
10h) were determined using X-ray crystallography so as to decipher the interactions 
responsible for their potency. All compounds show similar potency for hlGPa and rmGPb 
and, the active sites in hlGP and rmGP are identical in terms of sequence and structure 
therefore conclusions based on structural data obtained with rmGPb are directly applicable to 
hlGPa.  
 
The 2Fo-Fc and Fo-Fc electron density maps revealed that all five inhibitors were bound at 
the active site and clearly defined the position of each atom of the ligands (Figure 2). The 
superposition of the structures of free rmGPb and the rmGPb-inhibitor complexes over well-
defined residues (18– 49, 262–312, 326–829) gave r.m.s.d. values of 0.15, 0.20, 0.17, 0.16, 
and 0.19 Å for the 10a, 10b, 10c, 10d, and 10h, complexes, respectively, indicating that the 
binding of the inhibitors at the catalytic site did not trigger any major conformational change 
on the overall protein structure. 
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Figure 2. The REFMAC weighted 2Fo-Fc electron density maps of the bound ligands at the 
catalytic site contoured at 1.0 σ before the incorporation of the ligand molecules in the 
refinement process. The final models of the inhibitors are also shown. 
Each of the inhibitors binds at the catalytic site by anchoring the glucose moiety at a location 
previously observed for α-D-glucose and other glucose-based inhibitors [20, 46-50]. There the 
glucose moiety engages in hydrogen bonding (Table 5) and van der Waals interactions almost 
identical to those that have been previously observed for similar glucose analogues. 
Furthermore, three conserved water molecules mediate hydrogen bond interactions between 
the glucopyranose moiety of each ligand and residues Asp283, Tyr573, Lys574, Thr671, 
Ala673, Thr676, and the phosphate group of the cofactor PLP. 
Table 5: Potential hydrogen bond interactions of inhibitors with rmGPb residues at the catalytic 
site in the crystal. Hydrogen bonds are reported if the distance is less than 3.4 Å and the angle at 
the donor group is above 100°. Numbers shown are distances in Å.a 
Inhibitor atom Protein atoms 10a 10b 10c 10d 10h 
O2’ 
Asn284 (ND2) 3.1 3.1 3.1 3.0 2.6 
Try573 (OH) 3.0 3.1 3.0 3.1 3.1 
Glu672 (OE2) 3.0 3.2 3.2 3.2 3.3 
Water (O) 2.9 3.0 2.9 3.0 2.8 
Water (O) 2.8 2.8 2.8 2.8 2.8 
O3’ 
Glu672 (OE2) 2.6 2.6 2.6 2.7 2.7 
Ala673 (N) 3.3 3.2 3.2 3.2 3.3 
Ser674 (N) 3.1 3.1 3.1 3.1 3.1 
Gly675 (N) 3.1 3.2 3.2 3.2 3.3 
O4’ 
Gly675 (N) 2.9 2.9 2.8 2.8 2.8 
Water (O) 2.6 2.6 2.6 2.6 2.6 
O6’ 
His377 (ND1) 2.7 2.7 2.7 2.7 2.7 
Asn484 (ND2) 2.8 2.8 2.8 2.7 2.8 
N2 His377 (O) 2.7 2.7 2.7 2.7 2.9 
N5 Water (O) 3.0 3.0 2.9 2.9 2.8 
O17 
Glu287 (N) 3.2 - - - - 
Gly288 (N) 3.1 - - - - 
Water (O) 2.7 - - - - 
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Water (O) 3.3 - - - - 
Water (O) - 2.7 - - - 
Water (O) - 3.0 - - - 
O18 
Asn282 (ND2) 3.1 3.3 - - - 
Water (O) - 2.8 - - - 
Water (O) 2.8 - - - - 
Total 21 19 15 15 15 
a Atom numbering is as displayed in Table 4. 
 
The triazole linker participates in a hydrogen bond interaction with the main chain oxygen of 
His377 (Table 4), as was predicted by the modelling, and in water-mediated hydrogen bond 
interactions with the main chain nitrogen atoms of Gly135 and Leu136 through a conserved 
water molecule in all rmGPb ligand complexes. Similar interactions have been previously 
observed with other glucose derived inhibitors bound to rmGPb [46, 51], and the increased 
inhibitory potency of the 1,2,4-triazole compounds was ascribed to the hydrogen-bond 
forming capacity of the heterocyclic nitrogen atoms to the main chain oxygen of His377 and 
to water-mediated hydrogen bonding interactions with the sidechain atoms of Asp283 and the 
main chain atoms of Leu136.  
In total, 10a, 10b, 10c, 10d, and 10h engage in 116, 92, 90, 92, and 81 van der Waals 
interactions with protein residues at the active site of rmGPb, respectively (Figure 3). The 
phenyl ring A (c.f. Table 4) in 10a, 10b, 10c, and 10d is involved in van der Waals 
interactions with protein residues Glu88 and Asn284 while phenyl ring B (c.f. Table 4) is 
involved in van der Waals interactions with Asn282, Phe285, Phe286, and Arg292. These 
interactions have been also observed with other 1,2,4-triazole inhibitors and they were the 
source of the significant potency displayed by them [46, 51]. In addition the naphthyl ring of 
10h engages in van der Waals interactions with Glu88, Leu136, Asn283, and Ala383. 
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The carboxyl group of 10a is involved in hydrogen bond interactions with the main chain 
atoms of Glu287 and Gly288 and the side chain of Asn282, while it also participates in water-
mediated interactions with Lys289, Arg292, and Glu385 (Figure 3). The carboxyl group of 
10b participates in hydrogen bond interactions with the side chain of Asn282 and water-
mediated interactions with Tyr280, Glu287, Gly288, Glu296, Arg292, and Glu385 (Figure 3).  
 
All inhibitors except 10h bind similar at the active site and do not seem to cause any 
significant conformational change. The binding of 10h triggers a significant shift of the 280s 
loop (residues 282-289). The r.m.s. distance for all atoms of these residues between the 
rmGPb-10c and the rmGPb-10h complex structures is 1.0 Å with Asn282, Asn284, Phe285 
and Glu287 being the residues with the greatest difference (Figure 4). This conformational 
change may arise from the different orientation of the naphthyl ring in 10h with respect to the 
other four inhibitors studied here. The energy cost associated with this conformational change 
may also offer an explanation for the lower potency displayed by this compound in 
comparison to the potency of the other four inhibitors. 
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Figure 3. Diagrams of the binding of 10a (a), 10b (b), 10c (c), 10d (d), and 10h (e) at the active site of 
rmGPb. Van der Waals interacting protein atoms are shown bigger and in meshed spheres. 
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Figure 4. Superposition of the rmGPb-10h complex structure (maroon) and the free structure (grey).  
The small differences in the inhibitory potency between inhibitors bearing a carboxyl group 
(10a and 10b) and the unsubstituted non-polar ligands 10c and 10d could be attributed to the 
interactions of the carboxylates. Bulk desolvation effects will be associated with the 
negatively charged carboxylate going from the free unbound state to the bound state in the 
catalytic site.  Additionally, the carboxyl groups upon binding hydrogen-bond a water 
molecule placing it in close proximity (~3.3 Å) to the phenyl ring of Tyr280 (10a complex) or 
Phe286 (~3.7 Å; 10b complex), constituting unfavorable interactions. These unfavorable 
interactions are, however, counterbalanced by the hydrogen bond interactions of the carboxyl 
groups (O17 and O18, Table 5). In the 10c and 10d complexes no extra waters are brought 
into the catalytic site since they do not have any polar groups. Comparing 10c and 10d, their 
aromatic groups form 29 and 32 van der Waals interactions, respectively, at the rmGPb active 
site, indicating that they do not have significant differences in their protein interactions and 
hence they are almost equipotent. The better potency of inhibitor 10a with respect to 10b for 
rmGPb (and hlGPa) could be attributed to two additional hydrogen bond interactions of one 
of its carboxyl oxygen atoms with the main chain amides of Glu287 and Gly288 (Table 5). 
2.5 Pharmacokinetics Predictions 
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Early monitoring of the pharmacokinetic profiles of lead compounds is recommended to help 
avoid potential for failure in later stage drug development trials. The absorption, distribution, 
metabolism and excretion (ADME) properties of our synthesized compounds were calculated 
using QikProp 3.5 [25], the results of which are shown in Table 6. An orally active drug 
should have no more than one violation of Lipinski’s ‘rule of five’ [52] while for Jorgensen’s 
‘rule of three’ [53, 54] more drug-like molecules have fewer violations. All inhibitors except 
the least potent sulfamoyl derivative (10f) have just 0 or 1 violation of Lipinski’s ‘rule of 
five’. Considering Jorgensen’s ‘rule of three’, there was a maximum of one violation for the 
ligands. While the Caco-2 cell permeability (> 22 nm s-1) appears adequate for most ligands 
(~ 60 nm s-1), it is flagged for 10a, 10b and the sulfamoyl derivative 10f; the sensitive 
lipophilicity/solubility balance of β-D-glucose analogues with heterocyclic linkers has 
previously been highlighted [55, 56]. Polar surface areas (PSAs), however, are within the 
range of 95% of known drugs (10f excepted) although they are close to or above (10a and 
10b) Veber at al.’s [57] recommended value of < 140 Å2 for oral bioavailability. With respect 
to the carboxylic acid moiety of 10a and 10b, a wide variety of endogenous substances such 
as amino acids and triglycerides possess this group and it is often part of the pharmacophore 
of diverse classes of therapeutic agents with more than 450 of carboxylic acid-containing 
drugs currently marketed worldwide [58]. A diminished ability to passively diffuse across 
biological membranes is more relevant in the context of central nervous system (CNS) drug 
discovery [58]. All other properties (Table 6) are satisfactory for the studied ligands. The 
predicted degree of binding to human serum albumin (log Khsa) which affects bioavailability 
is -1.15 – -0.50 and within the range for 95% of known drugs (-1.5 – 1.5), while the log BB 
values (-3.6 – -2.1) predict that the inhibitors are unlikely to cross the blood-brain barrier. 
3. Conclusions 
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Docking is widely used to distinguish active from inactives chemotypes in virtual screening 
studies. Here, GP inhibitor screening in the form of QM/MM docking (QM-PLD) has been 
applied to identify novel 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives. The 
advantage of a computationally driven (QM/MM docking) approach to candidate selection is 
highlighted, with eight out of the nine selected compounds selected for synthesis revealing 
either moderate or strong activity (Ki’s < 100 µM) compared to only nine of eighteen in 
previous studies (Table 1). Five of the nine candidates had Ki’s < 10 µM, our defined 
threshold for ‘activity’, with 10a-d and 10h potent low µM inhibitors (rmGPa, hlGPa) and 
10a-c on the high nM range for rmGPa. X-ray crystallography studies of the protein-ligand 
complexes revealed that the addition of polar groups such as carboxyl to the bulky aromatic 
ligand substituents in the β-cavity (although it offers additional hydrogen bond interactions 
with protein residues) does not lead to improved potency since this group also attracts water 
molecules that are placed in close proximity of hydrophobic residues. Structural studies 
indicate that improvement of the potency might otherwise arise by the replacement of the 
carboxyl groups with another non-polar chemical entity. Carbohydrate-based compounds and 
triazoles have proven to be  important classes of compounds in the treatment or development 
of new clinical candidates for a number of conditions [59, 60]. The 3-(β-D-glucopyranosyl)-5-
substituted-1,2,4-triazoles studied here are predicted to have drug-like potential with only 
permeability flagged as a potential issue to efficacy. However, the compounds have in general 
(for six of the nine synthesized) better predicted Caco-2 cell permeabilities (by a factor of 3) 
than previously reported glucose analogues [10, 55, 56] and accordingly are to be considered 
in further follow up experiments (cellular and in vivo) for efficacy. 
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Table 6. Results of ADME property predictions for the different tautomers of the 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole  inhibitors studied in this work  
Inhibitor Lipinskis’s Rule of Five and Violations (V)[b]  Jorgensen’s Rule of Three and Violations (V)[b]  PSA [Å2][c] log Khsa
[d] log BB[e] 
 
Mr [Da] 
(<500) 
HBD[f] 
(≤5) 
HBA[g] 
(≤10) 
log P(o/w) 
(<5) 
V Caco-2 [nm s-1][h] 
(>22) 
log S 
(>-5.7) 
NMP[i] 
(<7) 
V  
(<140 Å2) 
  
10a 
 
427.4 6 10 -0.2 1 1.6* -3.9 6 1 185.1 -0.85 -3.5* 
10b 
 
401.4 6 10 -0.7 1 1.6* -3.4 6 1 185.0 -0.94 -3.3* 
10c 
 
395.4 5 8 0.6 0 61.9 -4.2 7 1 135.6 -0.43 -2.2 
10d 
 
383.4 5 8 0.5 0 61.7 -3.9 6 0 135.6 -0.50 -2.2 
10e 
 
383.4 5 8 0.5 0 61.8 -3.9 6 0 135.6 -0.50 -2.2 
10f 
 
386.4 7* 11 -2.8* 2 2.9* -2.6 6 1 201.0* -1.15 -3.6* 
10h 
 
357.4 5 8 -0.1 0 57.1 -3.4 6 0 137.0 -0.61 -2.1 
10i 
 
407.4 5 8 0.8 0 61.8 -4.3 7 1 135.6 -0.38 -2.2 
10j 
 
431.4 5 8 1.0 0 59.7 -4.5 7 1 137.0 -0.30 -2.2 
Range
[j]
 130-725 0-6 2-20 -2.0-6.5 - <25 poor;              > 
500 great 
-6.5-
0.5 
1-8 - 7-200 -1.5-1.5 -3.0-1.2 
[a] ADME data were calculated as described in the text using Qikprop 3.5; predicted properties outside the range for 95% of known drugs are indicated with an asterisk (*). [b] 
Rules as listed in the columns, with any violations of the rules highlighted in italics. [c] PSA represents the van der Waals (polar) surface areas of N and O atoms; recommended 
PSA < 140  Å2 according to Veber et al. [57]. [d] log Khsa: predicted binding to human serum albumin. [e] log BB: the predicted blood-brain barrier coefficient. [f] Number of 
hydrogen bond donors. [g] Number of hydrogen bond acceptors. [h] Caco-2 cell permeability. [i] Number of primary metabolites. [j] Range for 95% of known drugs [61]. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
4. Experimental 
4.1 Computational details  
4.1.1 Protein Preparation 
The initial setup of the GPb receptor for docking was performed using Schrodinger’s “Protein 
Preparation Wizard” [25] and the solved co-crystallized complex with N-(2-naphthyl)-N´-(β-
D-glucopyranosyl)urea [5]. Water molecules within 5 Å of the native ligand were initially 
retained but deleted for subsequent docking. Bond orders were assigned and hydrogen atoms 
added, with protonation states for basic and acidic residues based on residue pKa values at 
normal pH (7.0) calculated using PROPKA [62]. Subsequent optimization of hydroxyl 
groups, histidine protonation states and C/N atom “flips”, and side-chain O/N atom flips of 
Asn and Gln was based on optimizing hydrogen bonding patterns. The phosphate in 
pyridoxal-phosphate (PLP) was assigned in monoanionic form. Finally, an “Impref” 
minimization of the GPb complex was performed using the OPLS-AA(2005) force field [63] 
to remove steric clashes and bad contacts but with heavy atoms constrained to within 0.3 Å 
(RMSD) of their crystallographic positions. 
 
4.1.2 Ligand Preparation 
Training and screening set ligands were prepared using a combination of Maestro, LigPrep 
3.5 and CombiGlide 3.8 [25]. For creation of the screening set database ligands consisting of 
diverse –R groups, “purchasable” acids (R-COOH), acid chlorides (R-COCl) and aldehydes 
(R-CHO) were downloaded from the ZINC docking database [26]. The following criteria 
were used as filters so that the final proposed ligands contained aryl substituents and were 
‘drug-like’:[52, 57] MWs ≤ 200, 224, and 240 Da with benzoyl chloride, benzoic acid and 
benzaldehyde used as substructures, respectively; 0 ≤ rotatable bonds ≤ 4. Using CombiGlide, 
the resulting reagents were ‘reacted’ with the 3-(β-D-glucopyranosyl)-1,2,4-triazole ‘core’ to 
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yield  the final 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles. 2335 distinct ligands 
constituted the screening set. LigPrep 3.5 generation of tautomers and favorable ionization 
states at pH = 7 ± 2 of the ligands resulted in three distinct tautomers of the triazole moiety (H 
on each of three N atoms); however, with only one triazole tautomer favored for the binding 
of all training set ligands to GPb (H on N2), only this tautomeric state was considered for 
docking of the screening set ligands.   
4.1.3 Docking Calculations 
Training Set Ligands: Flexible-ligand docking calculations were performed using Glide 6.8 in 
both standard- (SP) and extra-precision (XP) modes, as well as with QM-PLD [25, 64]. In the 
docking calculations with Glide, the shape and properties of the GPb catalytic site were first 
mapped onto grids with dimensions of 26.7 × 26.7 × 26.7 Å centred on the native co-
crystallized ligand. Positional constraints on the four glucose -OH oxygen atoms were applied 
(radius 1.5 Å) [65]. Standard parameters were otherwise applied for the Glide-SP and XP 
docking calculations. Post-docking minimization of the ligand poses was performed (with 
strain correction) and a maximum of 3 poses per ligand saved. Poses were ranked by ’docking 
score’. For the QM-PLD calculations, atomic partial charges of the output docking poses from 
Glide XP docking were reparametrized in the ‘field’ of the receptor (ESP fit charges) using 
QSite 6.8  [25] and single point energy QM/MM calculations. The ligands were then redocked 
using Glide-XP. 
Virtual Screening: Docking of the screening set ligands was performed using QM-PLD and 
with the same settings as for the training set ligands described above. 
 
4.1.4 ADME Property Predictions 
QikProp from Schrödinger [25] was used for the ADME property predictions. Specifically, 
Lipinski’s rules of five [52] (MW < 500, log P < 5, HBA ≤ 10, and HBD ≤ 5) and Jorgensen’s 
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rule of three [53, 54] (log S > -5.7, Caco-2 permeability > 22 nm/s, number of primary 
metabolites < 7) were applied to predict oral bioavailability. Calculations were performed in 
normal mode and are reported for the 1,2,4-triazole binding most stable tautomer (Table 1), 
with test calculations here and from previous studies [56] on β-D-glucopyranosyl 1,2,4-
triazole derivatives showing that the tautomeric state of the triazole has limited effect on the 
property predictions.   
 
4.2 Synthesis  
4.2.1 General methods 
Anhydrous toluene, m-xylene, CHCl3, EtOAc, CH3CN (P2O5), THF (Na, benzophenone), 
pyridine (KOH), MeOH (Mg) were prepared by distillation from the indicated drying agent. 
Reagents were purchased from commercial suppliers (Sigma-Aldrich, TCI, Alfa Aesar) and 
used without further purification. TLC was carried out on precoated plates (DC-Alurolle 
Kieselgel 60, F254, Merck), and the spots were visualized under UV light and by gentle 
heating. Column chromatography was performed on silica gel (Kieselgel 60, 63-200 µm, 
Molar Chemicals). 1H, 13C NMR spectra were recorded on Bruker DRX 360 and Bruker DRX 
400 spectrometers. TMS (1H) or resonance peak of the solvent (13C) was used as reference. 
Mass spectra were obtained by a Bruker micrOTOF-Q instrument. Microanalyses were 
performed on an Elementar Vario Micro Cube. Optical rotations were determined with a 
Perkin-Elmer 241 polarimeter at rt. 
 
4.2.2 General procedure I for the synthesis of 4-benzyl-3-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-5-substituted-1,2,4-triazoles (6) 
The solution of an N-benzyl-arenecarboxamide (5, 2 equiv.) in SOCl2 (5 mL/mmol) was 
heated at boiling temp. for 2 h then the excess of SOCl2 was removed under diminished 
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pressure. The residue was dissolved in anhydrous toluene and evaporated in order to remove 
the traces of the reagent. 5-(2,3,4,6-Tetra-O-benzoyl-β-D-glucopyranosyl)tetrazole (1, 1 
equiv.) in anhydrous m-xylene (15 mL/mmol) was added and the mixture was refluxed until 
disappearance of the tetrazole (TLC, 4:1 toluene-AcOH). After evaporation of the solvent the 
residue was purified by column chromatography. 
 
4.2.3 General procedure II for the synthesis of 3-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-5-substituted-1,2,4-triazoles (7) from N1-tosyl-C-(2,3,4,6-tetra-O-
benzoyl-β-D-glucopyranosyl)formamidrazone (2) 
N1-Tosyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamidrazone (2) was dissolved 
in anhydrous CHCl3 (15 mL/mmol) and anhydrous pyridine (3.0 equiv.) was added. The 
mixture was cooled in an ice bath, and the solution of an aroyl chloride (3.0 equiv.) in 
anhydrous CHCl3 (5 mL/mmol) was added dropwise over 15 minutes. Subsequently, the 
mixture was stirred at rt and monitored by TLC (3:1 EtOAc-hexane). After total consumption 
of the starting material (2 days) the mixture was diluted with CHCl3 and extracted with water. 
The organic phase was dried over MgSO4 and concentrated under diminished pressure. The 
obtained residue was dissolved in THF (20 mL/mmol) and TBAF (1 M solution in THF, 2.0 
equiv.) was added. The reaction mixture was boiled for 24 h and then it was concentrated and 
purified by column chromatography. 
 
4.2.4 General procedure III for the preparation of N-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosylcarbonyl)thioamides (8) 
A mixture of C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formic acid (3) and SOCl2 (10 
mL/mmol) was boiled under reflux for two hours, then the excess of the reagent was removed 
under diminished pressure. Last traces of SOCl2 were removed by co-evaporations with dry 
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toluene. The resulting acid chloride (4) was dissolved in anhydrous CH3CN (15 mL/mmol), 
and a solution or a suspension of the corresponding thioamide (1.2 equiv.) and pyridine (1.2 
equiv.) in anhydrous CH3CN (30-120 mL/mmol depending on the solubility of the thioamide) 
was added dropwise over 20 minutes. The reaction mixture was stirred at rt, and monitored by 
TLC (1:1 hexane-EtOAc). After complete conversion the solvent was removed and the 
residue was purified by column chromatography. 
 
4.2.5 General procedure IV for the preparation of 3-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-5-substituted-1,2,4-triazoles (7) from N-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosylcarbonyl)thioamides (8) 
To a solution of an N-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosylcarbonyl)thioamide (8) in 
anhydrous pyridine (10 mL/mmol) hydrazine monohydrate (1.2 equiv.) was added, and the 
reaction mixture was stirred at rt. After disappearance of the starting material (monitored by 
TLC, 1:1 hexane-EtOAc) the solvent was removed and the residue was purified by column 
chromatography. 
 
N-Benzyl and O-benzoyl protecting groups were removed by standard methods to give the 
test compounds 10. Detailed procedures for deprotections as well as compound 
characterization are described in the Supporting Information. 
4.3 Kinetics 
Rabbit muscle GPb (rmGPb) was purified from rabbit skeletal muscle following the protocol 
developed by Fischer & Krebs [66] with slight modifications [67] while rmGPa was produced 
by phosphorylation of rmGPb [51]. Human liver GPa (hlGPa) was produced following a 
previously described protocol [51]. Kinetic studies were performed at 30 °C in the direction 
of glycogen synthesis using 3 µg/mL of the rabbit muscle enzymes, or 1 µg/mL hlGPa in a 30 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28 
 
mM imidazole/HCl buffer (pH 6.8) containing 60 mM KCl, 0.6 mM EDTA, and 0.6 mM 
dithiothreitol, using constant concentrations of glycogen (0.2% w/v), AMP (1 mM; only for 
the rmGPb experiments), and various concentrations of Glc-1-P and inhibitors. Initial 
velocities were calculated from the pseudo-first order rate constants measuring the release of 
orthophosphate ions spectrophotometrically [68] at five time-intervals. For the calculation and 
statistical evaluation of the kinetic parameters, the non-linear regression program Grafit [69] 
was employed. 
4.4 X-ray Crystallography 
rmGPb-inhibitor complexes were formed by diffusion of 10 mM solution of the inhibitors in 
the crystallization media supplemented with DMSO (15 %, v/v) in preformed rmGPb crystals 
[70] at room temperature for 3 hours prior to data collection. X-ray diffraction data were 
collected using synchrotron radiation on station I04 (λ=0.9795 Å) at Diamond Synchrotron 
Radiation Source in Oxford, U.K. at room temperature on a Pilatus 6M detector. To avoid 
crystal radiation damage the crystal was translated five times. Crystal orientation, integration 
of reflections, inter-frame scaling, partial reflection summation, and data reduction was 
performed by the program XDS [71]. Scaling and merging of intensities were performed by 
Aimless [72] and the optimum resolution was selected based on the CC1/2 criterion [73]. 
Crystallographic refinement of the complexes was performed by maximum-likelihood 
methods using REFMAC [74] with starting model the structure of the native T state rmGPb 
complex determined at 1.9 Å resolution (Leonidas et al, unpublished results). Ligand 
molecule coordinates and topologies were constructed using JLigand [75] and they were fitted 
to the electron density maps by adjusting of their torsion angles. A summary of the data 
processing and refinement statistics for the inhibitor complex structures is given in Table 1. 
The refinement was validated by the PDB_REDO server [76]. As there were more than 5 
reflections per atom available, both an isotropic and an anisotropic B-factor model were 
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considered, and the isotropic B-factor model was selected based on the Hamilton R ratio test. 
The stereochemistry of the protein residues was validated by MolProbity [77]. Hydrogen 
bonds and van der Waals interactions were calculated with the program CONTACT as 
implemented in CCP4 [78] applying a distance cut off 4.1 Å and 4.0 Å, respectively. Figures 
were prepared with CCP4 Molecular Graphics [79]. The coordinates of the new structures 
have been deposited with the RCSB Protein Data Bank (http://www.rcsb.org/pdb) with codes 
as presented in Table 7. 
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Table 7: Summary of the diffraction data processing and refinement statistics for the rmGPb inhibitor complexes. Values in parentheses are for the 
outermost shell. 
rmGPb complex 10a 10b 10c 10d 10h 
Data Processing and collection statistics 
Resolution (Å) 128 – 2.20  
(2.27 – 2.20) 
129 – 1.90 
(1.94 – 1.90) 
129 – 1.90 
(1.94 – 1.90) 
116 – 1.90 
(1.94 – 1.90) 
91 – 2.20 
(2.27 – 2.20) 
Reflections measured 528815 1141897 1149248 1146204 729941 
Unique reflections 49885 76655 75805 77397 50194 
Rmerge 0.229 (0.742) 0.163 (0.799) 0.162 (0.703) 0.143 (0.996) 0.213 (1.137) 
Completeness (%) 99.8 (99.7) 99.5 (98.9) 98.1 (96.9) 100 (100) 100 (100) 
< I /σ(I) > 10.3 (5.5) 10.8 (3.4) 11.6 (4.1) 12.2 (3.1) 9.1 (2.8) 
Multiplicity 10.6 (9.7) 14.9 (15.3) 15.2 (15.7) 14.8 (15.1) 14.5 (14.9) 
CC1/2 0.984 (0.946) 0.993 (0.939) 0.995 (0.960) 0.995 (0.933) 0.954 (0.885) 
B Wilson (Å2) 23.1 28.7 27.4 29.9 30.3 
Reflections used for 
refinement 47423 72835 72024 73452 47694 
No of water molecules 276 250 248 242 203 
No of ligand atoms 31 29 29 28 26 
R (Rfree) (%) 13.6 (16.7) 13.7 (16.1) 13.3 (16.0) 13.5 (15.6) 14.2 (17.2) 
Outer shell R (Rfree) (%) 15.7 (19.4) 18.1 (21.9) 16.9 (21.9) 19.0 (22.3) 20.7 (24.4) 
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r.m.s.d. in bond lengths (Å) 0.009 0.010 0.017 0.010 0.010 
r.m.s.d. in bond angles (°) 1.27 1.31 1.71 1.32 1.35 
Average Β (Å2) 
Protein atoms 21.8 28.8 27.4 30.0 30.5 
Water molecules 34.6 43.1 40.6 42.8 41.1 
Ligand atoms 26.7 26.9 28.2 30.1 33.0 
PDB entry 6F3J 6F3L 6F3R 6F3S 6F3U 
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